Compare Stocks

→ The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.27 -1.2%	$9.03	$2.09 ▼ $14.84	$515.37M	0.22	5.12 million shs	1.70 million shs
AMT American Tower	$181.35 +1.5%	$188.97	$154.58 ▼ $219.10	$84.57B	0.71	2.47 million shs	2.59 million shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+0.82%	+15.09%	-19.03%	-30.83%	+48.99%
AMT American Tower	-1.68%	+2.07%	-6.04%	-6.77%	-9.18%

Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	0.89 of 5 stars	3.3	1.0	0.0	0.0	1.8	1.7	0.0
AMT American Tower	4.8906 of 5 stars	3.5	5.0	2.5	3.1	2.6	2.5	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.50	Moderate Buy	$15.00	106.33% Upside
AMT American Tower	2.91	Moderate Buy	$221.91	22.37% Upside

Current Analyst Ratings

Latest ADR, AMT, ALT, and ADO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2024	AMT American Tower	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$243.00 ➝ $223.00
5/1/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$228.00 ➝ $220.00
5/1/2024	AMT American Tower	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$226.00 ➝ $248.00
4/29/2024	ALT Altimmune	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00

(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,198.54	N/A	N/A	$2.75 per share	2.64
AMT American Tower	$11.14B	7.59	$9.89 per share	18.34	$23.30 per share	7.78

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Confirmed)
AMT American Tower	$1.48B	$4.42	41.03	17.57	1.43	18.42%	18.45%	3.11%	7/25/2024 (Estimated)

Latest ADR, AMT, ALT, and ADO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	ALT Altimmune	-$0.36	N/A	+$0.36	N/A	N/A	N/A
4/30/2024	Q1 2024	AMT American Tower	$2.43	$1.96	-$0.47	$1.96	$2.79 billion	$2.83 billion
3/27/2024	Q4 2023	ALT Altimmune	-$0.35	-$0.33	+$0.02	-$0.12	N/A	$0.04 million
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.57%	+12.50%	146.61%	N/A

Latest ADR, AMT, ALT, and ADO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.39	0.85	0.85

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.18%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.51 million	Optionable

ADR, AMT, ALT, and ADO Headlines

Source	Headline
	Insider Selling: American Tower Co. (NYSE:AMT) Director Sells 700 Shares of Stock marketbeat.com - May 7 at 6:52 PM
	UNIVEST FINANCIAL Corp Sells 4,796 Shares of American Tower Co. (NYSE:AMT) marketbeat.com - May 7 at 5:14 PM
	The 3 Best REITs to Buy in May 2024 investorplace.com - May 7 at 12:35 PM
	Perfect Pullback Play with a Safe 8.4% Payout marketbeat.com - May 6 at 10:03 PM
	International Markets and American Tower (AMT): A Deep Dive for Investors zacks.com - May 6 at 3:06 PM
	National Bank of Canada FI Has $47.48 Million Holdings in American Tower Co. (NYSE:AMT) marketbeat.com - May 6 at 1:39 PM
	American Tower: A 'Wide Moat' Juggernaut That Deserves Shelf Space In Your Portfolio seekingalpha.com - May 6 at 7:13 AM
	American Tower Co. (NYSE:AMT) Shares Acquired by TCG Advisory Services LLC marketbeat.com - May 5 at 7:52 PM
	American Tower Co. (NYSE:AMT) Shares Bought by Los Angeles Capital Management LLC marketbeat.com - May 4 at 10:25 AM
	American Tower Co. (NYSE:AMT) Shares Sold by Fisher Asset Management LLC marketbeat.com - May 3 at 6:13 PM
	Raymond James Upgrades American Tower (NYSE:AMT) to "Strong-Buy" americanbankingnews.com - May 3 at 6:20 AM
	BMO Capital Markets Lowers American Tower (NYSE:AMT) Price Target to $220.00 americanbankingnews.com - May 3 at 5:32 AM
	Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $288.53 Million Position in American Tower Co. (NYSE:AMT) marketbeat.com - May 2 at 9:52 PM
	Raymond James Upgrades American Tower (AMT) msn.com - May 2 at 8:12 PM
	American Tower (NYSE:AMT) Price Target Lowered to $223.00 at Scotiabank americanbankingnews.com - May 2 at 7:20 AM
	What the Options Market Tells Us About American Tower benzinga.com - May 1 at 7:12 PM
	American Tower (AMT) Q1 2024 Earnings Call Transcript fool.com - May 1 at 7:12 PM
	New York Life Investment Management LLC Buys 32,392 Shares of American Tower Co. (NYSE:AMT) marketbeat.com - May 1 at 5:46 PM
	Scotiabank Trims American Tower (NYSE:AMT) Target Price to $223.00 marketbeat.com - May 1 at 4:33 PM
	American Tower inches higher after Raymond James upgrades on growth prospects msn.com - May 1 at 2:12 PM
	American Tower Corporation (NYSE:AMT) Q1 2024 Earnings Call Transcript finance.yahoo.com - May 1 at 2:12 PM
	REITs Continue To Clobber Q1 Estimates finance.yahoo.com - May 1 at 2:12 PM
	American Tower: Strong Q1 Performance and Positive Growth Trajectory Justify Buy Rating markets.businessinsider.com - May 1 at 9:11 AM
	The Analyst Landscape: 6 Takes On American Tower markets.businessinsider.com - May 1 at 9:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
April 24, 2024 10:40 AM
View Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?
April 30, 2024 9:25 AM
View CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?
3 Companies Buying Back Cheap Stock Lately
April 29, 2024 6:23 AM
View 3 Companies Buying Back Cheap Stock Lately
Undervalued UnitedHealth Group Won’t Be For Long
April 16, 2024 10:53 AM
View Undervalued UnitedHealth Group Won’t Be For Long
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial